Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric open-label study of regular marstacimab prophylaxis versus prior 12-month standard treatment in severe hemophilia A or B
CTR20231552Phase 3Active
- Sponsor
- ---/ 辉瑞投资有限公司
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of marstacimab in hemophilia A, hemophilia B (HB), sponsored by ---/ 辉瑞投资有限公司. Started Aug 2023; status: active.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20231552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231552.